To investigate the association of MUC16 mutation with established genomic factors associated with ICI response, we began with tumor mutational burden, because it has been the most widely reproduced biomarker for ICI therapy.33 We found that, in this pan-cancer data set, patients with MUC16 mutations exhibited significantly higher tumor mutational burden than those without them (median [IQR], 230 [93-595] mutations vs 48 [25-92] mutations; difference, 182 mutations; 95% CI, 164-199 mutations; P < .001, Mann-Whitney U test) (Figure 1A). Here, MUC16 is linked to neoplasm.